

Special Issue

Drug Delivery for Cardiovascular Diseases

Message from the Guest Editor

Small molecules are used to treat cardiovascular system diseases (CVDs), and different formulations have been developed to improve solubility, PK, and efficacy/safety. Examples of classically used drugs include diltiazem, isosorbide-5-mononitrate, metoprolol, propafenone, and aspirin. Formulations of valsartan, atenolol, atorvastatin, and ezetimide have recently been developed. Emerging evidence indicates that nano-drug delivery systems (NDDSs) have the ability to increase stability and water drug solubility, increase the uptake of target cells, improve the PK, and can be used to deliver biologics and small molecules by various routes. NDDSs may improve the effectiveness of drugs in CVDs. However, less attention has been dedicated to safety. Nanomaterials can be highly reactive, generating ROS and affecting macromolecules, which leads to cell growth inhibition or cell cycle modification. In special populations including old people with chronic CVDs or in neonatal/pediatric patients affected by rare diseases, the efficacy and safety of these formulations need to be evaluated.

Guest Editor

Prof. Dr. Domenico Tricarico

Section of Pharmacology, Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Via Orabona 4, 70125 Bari, Italy

Deadline for manuscript submissions

closed (30 April 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/57392

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).